

## Table of Contents

<b>Abstract.....</b>	<b>III</b>
<b>Zusammenfassung.....</b>	<b>V</b>
<b>1 Introduction.....</b>	<b>1</b>
<b>1.1 Post-translational protein modifications.....</b>	<b>1</b>
<b>1.2 ADP-ribosylation.....</b>	<b>2</b>
1.2.1 Writers of ADP-ribosylation .....	3
1.2.2 The ARTC family of eukaryotic ADP-ribosyltransferases.....	4
1.2.3 The ARTD family of eukaryotic ADP-ribosyltransferases.....	4
1.2.3.1 ARTD1, ARTD2 and ARTD3 - DNA-dependent ARTDs .....	7
1.2.3.2 ARTD7, ARTD8 and ARTD9 - macrodomain containing ARTDs.....	10
1.2.3.3 ARTD10 - unique ubiquitin interaction motifs.....	12
1.2.3.4 ARTD12, ARTD13 and ARTD14 - CCCH ARTDs.....	17
1.2.3.5 ARTD15 - unique transmembrane domain.....	20
1.2.4 Readers of ADP-ribosylation .....	20
1.2.4.1 Macrodomains - structurally conserved ADPr binding modules.....	21
1.2.4.2 Poly(ADP-ribose)-binding peptide motif.....	23
1.2.4.3 Tryptophan-tryptophan-glutamate domain .....	24
1.2.4.4 Poly(ADP-ribose)-binding zinc finger domain.....	25
1.2.4.5 Oligonucleotide/oligosaccharide-binding fold.....	25
1.2.4.6 Additional PAR-binding modules.....	26
1.2.5 Erasers of ADP-ribosylation .....	27
1.2.5.1 Poly(ADP-ribose) glycohydrolase .....	28
1.2.5.2 Poly(ADP-ribose) and serine mono(ADP-ribose) glycohydrolase ARH3.....	29
1.2.5.3 Nudix hydrolases .....	29
1.2.5.4 Macrodomain containing protein 1 and 2 .....	30
1.2.5.5 Terminal ADP-ribose protein glycohydrolase 1 .....	31
1.2.5.6 Viral macrodomains .....	32
<b>1.3 Human papillomaviruses.....</b>	<b>34</b>
1.3.1 Structure and regulation of the viral genome .....	34
1.3.2 The life cycle of human papillomaviruses .....	36
1.3.3 Function of transforming proteins.....	39
1.3.3.1 E6 .....	39
1.3.3.2 E7 .....	43
1.3.4 From infection to tumor progression.....	47
1.3.5 The immortal life of Henrietta Lacks .....	50
1.3.6 ADP-ribosylation and HeLa cells .....	50
<b>1.4 Aims of this work .....</b>	<b>52</b>
<b>2 Results and Discussion.....</b>	<b>53</b>
<b>2.1 Characterization of an <i>Artd10</i> knockdown mouse model.....</b>	<b>53</b>
2.1.1 Breeding of transgenic <i>Artd10<sup>shTet</sup>/WT</i> mice .....	53
2.1.2 <i>Artd10</i> knockdown efficiencies in different organs of <i>Artd10<sup>shTet</sup>/WT</i> mice .....	57
2.1.3 Long-term induction of an <i>Artd10</i> knockdown in mice .....	60
2.1.4 Characterization of mouse embryonic fibroblasts.....	73
2.1.4.1 Gender determination of mouse embryonic fibroblasts .....	73
2.1.4.2 <i>Artd10</i> knockdown efficiency in mouse embryonic fibroblasts.....	74

## TABLE OF CONTENTS

---

2.1.4.3 Reduced <i>Ardt10</i> expression does not affect cell growth in MEFs .....	75
2.1.4.4 <i>Ardt10</i> is regulated by IFN $\alpha$ .....	77
2.1.5 <i>Ardt10</i> knockdown does not impact intestinal organoid integrity .....	79
2.1.6 Crossing of <i>Ardt10<sup>shTet</sup>/<sup>WT</sup></i> animals with <i>Ardt10<sup>WT</sup>/<sup>WT</sup></i> /Alb-Cre $^+$ mice .....	81
2.1.7 Constitutive hepatocyte-specific <i>Ardt10</i> knockdown in mice.....	83
2.1.8 Conclusion and future perspectives - part I.....	85
2.1.8.1 Breeding performance decreased over time.....	86
2.1.8.2 Verification of an <i>Ardt10</i> knockdown in <i>Ardt10<sup>shTet</sup>/<sup>WT</sup></i> mice .....	86
2.1.8.3 Reduced body weight, enlarged ceca and spinal abnormalities were observed in doxycycline-treated <i>Ardt10<sup>shTet</sup>/<sup>WT</sup></i> mice .....	87
2.1.8.4 Doxycycline administration and <i>Ardt10</i> knockdown did not cause severe changes in liver histology, hematopoietic parameters or clinical pathology markers.....	87
2.1.8.5 Characterization of an inducible <i>Ardt10</i> knockdown in mouse embryonic fibroblasts derived from <i>Ardt10<sup>shTet</sup>/<sup>WT</sup></i> and <i>Ardt10<sup>WT</sup>/<sup>WT</sup></i> embryos .....	88
2.1.8.6 <i>Ardt10</i> knockdown in intestinal organoid cultures .....	89
2.1.8.7 Constitutive hepatocyte-specific knockdown of <i>Ardt10</i> .....	90
2.1.8.8 <i>In vivo</i> inhibition of <i>Ardt10</i> .....	91
<b>2.2 Interplay between interferon-regulated mono-ADP-ribosylation and human papillomavirus E6 and E7 proteins .....</b>	<b>93</b>
2.2.1 Mono-ARTDs are regulated by IFN $\alpha$ .....	93
2.2.2 Viral macromodains possess robust and broad mono-ADP-ribosylhydrolase activity .....	96
2.2.3 Poly-ADP-ribose chains are inefficiently hydrolyzed by viral macromodains.....	99
2.2.4 Mutational analysis of the CHIKV MD suggests catalytically important amino acids .....	102
2.2.5 HPV E7 proteins and partially E6 are substrates of IFN $\alpha$ -regulated mono-ARTDs .....	105
2.2.6 HPV E6 and E7 proteins are no mono-ADP-ribosylhydrolases .....	112
2.2.7 HPV E6 proteins impair enzymatic activity of mono-ARTDs .....	114
2.2.8 HPV E6 and E7 expression remains unchanged upon induction of <i>mono-ARTDs</i> .....	123
2.2.9 Adenovirus E1A protein - an orthologue to E7 - is a MARylation substrate .....	125
2.2.10 Towards mapping of ADP-ribosylation sites in HPV 16 E7 .....	127
2.2.11 Impact of exogenous <i>ARTD</i> expression on cell growth of HPV-positive cell lines.....	133
2.2.12 Conclusion and future perspectives - part II .....	137
2.2.12.1 MARylation participates in antiviral defense .....	138
2.2.12.2 Mono-ADP-ribosylation is a new PTM of certain HPV E proteins.....	139
2.2.12.3 HPV E6 hampers automodification and substrate MARylation .....	141
2.2.12.4 ADP-ribosylation restricts hyperproliferation of HPV-positive cells? .....	142
<b>3 Experimental Procedures .....</b>	<b>143</b>
3.1 Kits.....	143
3.2 Oligonucleotides .....	143
3.3 Plasmids .....	144
3.4 Antibodies .....	149
3.4.1 Primary antibodies .....	149
3.4.2 Secondary antibodies .....	149
3.5 Work with mice .....	149
3.5.1 Mice strains .....	149
3.5.2 Animal maintenance .....	149
3.5.3 Generation of an inducible <i>Ardt10</i> knockdown mouse model .....	150
3.5.3.1 Doxycycline-inducible shRNA cassette.....	151
3.5.4 Breeding of <i>Ardt10<sup>shTet</sup>/<sup>WT</sup></i> and <i>Ardt10<sup>sh</sup>/<sup>WT</sup></i> /Alb-Cre $^+$ mice .....	152

---

3.5.5	Generation of mouse embryo fibroblasts .....	153
3.5.6	Doxycycline-induced <i>Artd10</i> knockdown.....	153
3.5.7	Blood collection, resection and sample preparation.....	154
3.5.8	Organoid isolation from the small intestine .....	154
<b>3.6</b>	<b>Work with bacteria.....</b>	<b>155</b>
3.6.1	Bacterial strains.....	155
3.6.2	Bacterial cultivation .....	155
3.6.3	Heat shock transformation .....	156
<b>3.7</b>	<b>Cell-based assays.....</b>	<b>156</b>
3.7.1	Eukaryotic cell lines .....	156
3.7.2	Cell cultivation .....	157
3.7.3	Trypsinization .....	158
3.7.4	Freezing and thawing of cells .....	158
3.7.5	Cell seeding .....	159
3.7.6	Passaging of organoids.....	159
3.7.7	Calcium phosphate transfection of plasmid DNA.....	159
3.7.8	FuGENE® transfection of plasmid DNA .....	160
3.7.9	Retroviral transduction and generation of stable MEF cell lines .....	160
3.7.10	Retroviral transduction and generation of stable HEK293, CaSki, SiHa and C4-I cell lines ...	161
3.7.11	Induction of an <i>Artd10</i> knockdown in iMEFs using doxycycline.....	162
3.7.12	IFN $\alpha$ -treatment of cells.....	162
3.7.13	Growth curves.....	162
3.7.14	Colony formation assay .....	162
3.7.15	Flow cytometric analysis of cell cycle .....	162
<b>3.8</b>	<b>Nucleic acid-related methods.....</b>	<b>163</b>
3.8.1	Agarose gel electrophoresis .....	163
3.8.2	Plasmid preparation from bacterial cultures .....	163
3.8.3	Restriction digest .....	163
3.8.4	Gateway cloning .....	164
3.8.5	Isolation of genomic DNA from mouse tissue .....	164
3.8.6	Polymerase Chain Reaction .....	165
3.8.7	Isolation of total RNA from cultured cells .....	166
3.8.8	RNA extraction from whole tissue .....	166
3.8.9	Photometric quantitation of nucleic acids .....	166
3.8.10	cDNA synthesis and quantitative real-time PCR .....	167
<b>3.9</b>	<b>Protein-related methods .....</b>	<b>168</b>
3.9.1	Purification of recombinant glutathione-S-transferase-tagged proteins .....	168
3.9.2	Purification of recombinant hexahistidine-tagged proteins .....	169
3.9.3	ADP-ribosylation assay .....	170
3.9.4	Hydrolase assay .....	171
3.9.5	<i>In vitro</i> -Pulldown .....	172
3.9.6	Preparation of cell lysates .....	172
3.9.7	Denaturing polyacrylamide gel electrophoresis .....	173
3.9.8	Coomassie staining .....	173
3.9.9	Western blot analysis .....	174
3.9.10	Histology and immunohistochemistry .....	175
<b>4</b>	<b>References .....</b>	<b>176</b>
<b>5</b>	<b>Appendix .....</b>	<b>198</b>

## TABLE OF CONTENTS

---

5.1	Supplementary information .....	198
5.2	List of figures.....	200
5.3	List of tables.....	201
5.4	Abbreviations .....	202
5.5	Curriculum vitae.....	206
5.6	Scientific contributions.....	207
5.7	Eidesstattliche Erklärung.....	209
5.8	Danksagung .....	210